$0.02
(1.90%)
Add to watchlist
Create an alert
Stocks and Shares ISAMustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs into potential cures for cancers and autoimmune diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR T) therapies. Its pipeline is focused in two core areas: CAR T therapies for autoimmune diseases and hematologic malignancies and CAR T therapies for solid tumors. It is developing a CAR T therapy for hematologic malignancies and autoimmune diseases in partnership with Fred Hutchinson Cancer Center targeting CD20 and for solid tumors in partnership with City of Hope National Medical Center targeting IL13Ra2. It has also partnered with Nationwide Children’s Hospital for a herpes simplex virus type 1 oncolytic virus to enhance the activity of MB-101 for the treatment of patients with high-grade malignant brain tumors.
Company Information
About this company
Key people
Michael S. Weiss
Executive Chairman of the Board
Manuel Litchman
President, Chief Executive Officer, Interim Chief Financial Officer, Director
David Jin
Director
Lindsay A. Rosenwald
Director
Adam J. Chill
Independent Director
Neil Herskowitz
Independent Director
Michael J. Zelefsky
Independent Director
Click to see more
Key facts
- Shares in issue6.45m
- EPICMBIO
- ISINUS62818Q3020
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$7.66m
- Employees6
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.